The SAFFRON data is a major derisking event for ORPATHYS' global approval pathway, significantly increasing the probability of regulatory submissions in the US and EU. Traders should monitor for upcoming medical meeting presentations and regulatory filing announcements, which could serve as additional catalysts.
Drugs in focus
HCM drug pipeline →ORPATHYS
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 17 $12.56entry
- T+1 · 3mo ago +0.64%α +1.31% · $12.64
- T+5 · 3mo ago −3.03%α −1.83% · $12.18
- T+20 · 2mo ago +9.79%α +11.77% · $13.79
- T+60 · 7d ago +22.45%α +25.40% · $15.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus chemotherapy in MET-driven EGFR-mutated NSCLC patients who progressed on TAGRISSO. This is the first global Phase III trial to demonstrate both PFS and OS benefits in this setting, providing pivotal data to support global regulatory filings for the combination. The results de-risk the global registration pathway for ORPATHYS, a key pipeline asset co-developed with AstraZeneca, and address a significant unmet need in a large patient population.
Key Facts
- SAFFRON Phase III trial met primary endpoint of PFS and key secondary endpoint of OS with statistical significance vs platinum-based chemotherapy.
- Trial enrolled 338 patients across 230 centers in 29 countries.
- ORPATHYS + TAGRISSO is already approved in China based on the SACHI Phase III trial; SAFFRON data supports global registrations.
- Safety profile was consistent with known profiles of each medicine; no new safety findings.
- MET overexpression/amplification occurs in ~34% of tumors after progression on third-generation EGFR TKIs, representing a large addressable market.
Financial Impact
Positive top-line Phase III data for ORPATHYS in a global registration-enabling trial; no specific revenue or deal value disclosed in the filing.
Risk Factors
- Regulatory approval timelines and outcomes in ex-China markets remain uncertain.
- Competition from other MET-targeted therapies in development.
- ORPATHYS is commercialized by AstraZeneca, limiting HUTCHMED's direct revenue capture from global sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000049 |
| Document: hcm-20260817x6k.htm | 0001648257-26-000049 |
| Document: 0001648257-26-000049-index-headers.html | 0001648257-26-000049 |
| Document: 0001648257-26-000049-index.html | 0001648257-26-000049 |
| Document: 0001648257-26-000049.txt | 0001648257-26-000049 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers